Obio Technology (Shanghai) Future Growth
Future criteria checks 1/6
Obio Technology (Shanghai) is forecast to grow earnings and revenue by 55.9% and 17.7% per annum respectively. EPS is expected to grow by 44.5% per annum. Return on equity is forecast to be -2.6% in 3 years.
Key information
55.9%
Earnings growth rate
44.5%
EPS growth rate
Life Sciences earnings growth | 26.8% |
Revenue growth rate | 17.7% |
Future return on equity | -2.6% |
Analyst coverage | Low |
Last updated | 22 Jul 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 371 | -15 | 32 | 121 | 2 |
12/31/2025 | 311 | -60 | -160 | -62 | 2 |
12/31/2024 | 255 | -121 | -213 | -51 | 2 |
3/31/2024 | 234 | -138 | -465 | -120 | N/A |
12/31/2023 | 205 | -128 | -637 | -90 | N/A |
9/30/2023 | 213 | -66 | -730 | -56 | N/A |
6/30/2023 | 240 | -26 | -756 | -35 | N/A |
3/31/2023 | 249 | -5 | -672 | 18 | N/A |
12/31/2022 | 291 | 39 | -463 | 21 | N/A |
9/30/2022 | 306 | 59 | -221 | 83 | N/A |
6/30/2022 | 291 | 59 | -170 | 82 | N/A |
3/31/2022 | 281 | 57 | -266 | 57 | N/A |
12/31/2021 | 255 | 54 | -153 | 109 | N/A |
9/30/2021 | 231 | 52 | -148 | 78 | N/A |
12/31/2020 | 143 | 94 | -34 | 62 | N/A |
12/31/2019 | 63 | -37 | -59 | -23 | N/A |
6/30/2019 | 52 | -38 | -65 | -21 | N/A |
3/31/2019 | 47 | -33 | -62 | -12 | N/A |
12/31/2018 | 44 | -32 | -58 | -1 | N/A |
9/30/2018 | 39 | -23 | -52 | -6 | N/A |
6/30/2018 | 35 | -18 | -45 | -10 | N/A |
3/31/2018 | 31 | -19 | -40 | -12 | N/A |
12/31/2017 | 28 | -20 | N/A | -14 | N/A |
9/30/2017 | 25 | -14 | N/A | -9 | N/A |
6/30/2017 | 23 | -9 | N/A | -4 | N/A |
3/31/2017 | 21 | -8 | N/A | -3 | N/A |
12/31/2016 | 20 | -7 | N/A | -2 | N/A |
12/31/2015 | 14 | -1 | N/A | 2 | N/A |
12/31/2014 | 8 | -4 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688238 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688238 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688238 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688238's revenue (17.7% per year) is forecast to grow faster than the CN market (13.6% per year).
High Growth Revenue: 688238's revenue (17.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688238 is forecast to be unprofitable in 3 years.